Ovarian Cancer Clinical Trial
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer.
PURPOSE: This randomized phase II trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
To compare the efficacy of the selected IP chemotherapy regimen (Arm 3: IV paclitaxel and IP carboplatin plus day 8 IP paclitaxel) versus IV carboplatin plus paclitaxel (Arm 1) in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy. Nine month progressive rate post randomization is the primary endpoint for assessment of efficacy.
To compare IP plus IV chemotherapy versus IV carboplatin plus paclitaxel with respect to progression free survival and overall survival.
OUTLINE: This is a multicenter study. Patients are stratified according to cooperative group, residual disease (observable [e.g., macroscopic] disease that is evident at end of delayed primary debulking surgery vs no evidence of observable disease at end of delayed primary debulking surgery), reason for delayed primary debulking surgery at initial diagnosis (nonresectable disease vs other reasons), and timing of intraperitoneal catheter insertion (intra-operative catheter insertion vs post-operative insertion).
Phase II: Patients are randomized to 1 of 3 treatment groups.
ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-Feb-03)
ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles.
Patients also receive carboplatin IP on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
Expanded Phase II: Patients are randomized to 1 of 2 treatment groups.
Arm I: Patients receive paclitaxel and carboplatin as in phase II, arm I.
Arm III: Patients receive paclitaxel and cisplatin as in phase II, arm II or paclitaxel and carboplatin as in phase II, arm III.
Patients complete quality of life questionnaires EORTC QLQ-C30, ovarian cancer module (EORTC QLQ-OV28), and FACT/GOG-Ntx at baseline, on day 1 of courses 2 and 3, at 3, 6 and 12 months after completion of study treatment, and then annually until disease progression, death, or initiation of second-line therapy.
After completion of study treatment, patients are followed at 6 weeks, every 3 months for 2 years, every 6 months for 2 years, and then annually until progression, death, or initiation of second-line therapy.
Histologically confirmed ovarian epithelial, primary serous type peritoneal, or fallopian tube carcinoma
Patients with ovarian cancer of the clear cell histology are eligible. Histologic confirmation is preferably by biopsy or limited excision prior to neo-adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is based on cytology, histologic confirmation is required prior to randomization. Histologic confirmation can be obtained at the time of debulking surgery by intra-operative frozen section, thus permitting intra-operative randomization, or by final pathologic review of the resected specimen if randomization is to be performed following debulking surgery.
Initial FIGO stage IIB-III disease
Stage IV disease allowed provided the only criterion for stage IV disease is the presence of a pleural effusion confirmed to be associated with positive cytology for ovarian cancer
Completed ≥ 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy prior to the first debulking surgery
Meets the following criteria for surgical treatment prior to randomization:
Initial Diagnosis: No debulking surgery was attempted or completed.
The patient's first cytoreductive (debulking) surgery must be after neoadjuvant chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery must be completed no more than 4 weeks after commencing administering of the last cycle of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization.
Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and any additional procedures required to achieve maximal cytoreduction with residual disease of 1 cm or less as assessed by the surgeon at the end of surgery.
Delayed primary debulking surgery must be completed no more than 4 weeks after the last course of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization
Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and any additional procedures required to achieve maximal cytoreduction with residual disease of ≤ 1 cm as assessed by the surgeon at the end of surgery
No borderline ovarian tumors (i.e., tumors of low malignant potential) alone
No mucinous tumor
ECOG performance status 0-2
Life expectancy ≥ 12 weeks
Granulocyte count ≥ 1.5 x 10^9/L
Platelet count ≥ 100 x 10^9/L
Serum creatinine ≤ upper limit of normal (ULN) OR > ULN to ≤ 1.25 ULN provided measured creatinine clearance is > 60 mL/min
Serum bilirubin normal
AST/ALT ≤ 2.5 times ULN
Fertile patients must use effective contraception
Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires
Accessible for treatment and follow-up
No history of other malignancy, except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
No uncontrolled atrial or ventricular arrhythmias including second or third degree heart block unless managed with implanted pacemaker
Patients with a history of first degree heart block are eligible
No documented myocardial infarction within the past 6 months preceding randomization (pretreatment ECG evidence only of infarct will not exclude patients)
No diagnosis of bowel obstruction
No serious illness or medical condition which would not permit the patient to be managed according to protocol including, but not limited to, any of the following:
Prior allergic reactions to drugs containing cremophor or to compounds chemically related to cisplatin, paclitaxel, or carboplatin
Symptomatic congestive heart failure within the past 6 months or other conditions which would lead to a contraindication of a high-volume saline diuresis
History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent
Active uncontrolled infection
Persistent peripheral neuropathy or hearing loss ≥ grade 2 resulting from prior therapy
Extensive intraperitoneal adhesion intra- or post-operatively which would impede intraperitoneal treatment delivery
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No prior therapy for ovarian cancer, except for neoadjuvant platinum-based chemotherapy and surgery
No concurrent intraperitoneal adhesion barriers
No other concurrent anticancer treatment, including cytotoxic agents, biological response modifiers, immunotherapy, anticancer hormone therapy, or investigational drug therapy
No other concurrent experimental drugs or anticancer therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 50 Locations for this study
Springfield Missouri, 65804, United States
Springfield Missouri, 65807, United States
Oklahoma City Oklahoma, 73190, United States
Providence Rhode Island, 02905, United States
Salt Lake City Utah, 84132, United States
Tacoma Washington, 98415, United States
Calgary Alberta, T2N 4, Canada
Edmonton Alberta, T6G 1, Canada
Kelowna British Columbia, V1Y 5, Canada
Surrey British Columbia, V3V 1, Canada
Vancouver British Columbia, V5Z 4, Canada
Winnipeg Manitoba, R3E 0, Canada
Saint John New Brunswick, E2L 4, Canada
St. John's Newfoundland and Labrador, A1B 3, Canada
Halifax Nova Scotia, B3H 1, Canada
Kingston Ontario, K7L 5, Canada
London Ontario, N6A 4, Canada
Ottawa Ontario, K1H 8, Canada
Thunder Bay Ontario, P7B 6, Canada
Toronto Ontario, M5G 2, Canada
Montreal Quebec, H1T 2, Canada
Montreal Quebec, H2L 4, Canada
Montreal Quebec, H2W 1, Canada
Quebec City Quebec, G1R 2, Canada
Sherbrooke Quebec, J1H 5, Canada
Hospitalet de Llobregat Barcelona, 08908, Spain
Alcorcon Madrid, 28922, Spain
Barcelona , 08035, Spain
Barcelona , 08036, Spain
Barcelona , 08041, Spain
Madrid , 28009, Spain
Madrid , 28033, Spain
Madrid , 28040, Spain
Valencia , 46009, Spain
Valencia , 46010, Spain
Wirral Bebington, CH63 , United Kingdom
Middlesex Northwood, HA6 2, United Kingdom
London Tooting, SW17 , United Kingdom
Slough Wexham, SL2 4, United Kingdom
Manchester Withington, M20 4, United Kingdom
Edinburgh , EH4 2, United Kingdom
Leeds , LS9 7, United Kingdom
Liverpool , L8 75, United Kingdom
London , EC1M , United Kingdom
London , SW3 6, United Kingdom
London , W12 0, United Kingdom
London , W1T 4, United Kingdom
Manchester , M13 0, United Kingdom
Oxford , OX3 7, United Kingdom
Plymouth , PL6 8, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.